Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Stephanie Smilo

Nurse Practitioner, Acute Care Canton, MI Nurse Practitioner

NPI 1356893606 CMS profile 10956329

361 N Canton Center Rd, Canton, MI 48187

Open in the dashboard

General payments

$5,290

241 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stephanie Smilo of Canton, MI is reported in the CMS Open Payments database as having received $5,290 across 241 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner, Acute Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,891 86
2024 General $1,817 84
2023 General $823 31
2022 General $305 16
2021 General $454 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephanie Smilo
  • Nurse Practitioner, Acute Care median
  • Middle half of Nurse Practitioner, Acute Care
  • National median

In program year 2025, general payments to Stephanie Smilo were reported at $1,891. Among 11,827 Nurse Practitioner, Acute Care profiles paid that year, the median was $152 and the middle half received between $48 and $458.

Show as a table
Year Stephanie Smilo Nurse Practitioner, Acute Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $454 $123 $38–$327 $132
2022 $305 $130 $44–$369 $149
2023 $823 $144 $49–$410 $160
2024 $1,817 $146 $48–$433 $164
2025 $1,891 $152 $48–$458 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $966 40 payments
  2. Regeneron Healthcare Solutions, Inc. $619 19 payments
  3. Novartis Pharmaceuticals Corporation $546 32 payments
  4. Sun Pharmaceutical Industries Inc. $529 24 payments
  5. AbbVie, Inc. $447 26 payments
  6. Genzyme Corporation $392 18 payments
  7. Lilly USA, LLC $293 14 payments
  8. Incyte Corporation $210 11 payments
  9. E.R. Squibb & Sons, L.L.C. $206 6 payments
  10. UCB, Inc. $176 8 payments
  11. Other $907 43 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,814 236 payments
  2. Education $476 5 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $885 36 payments
  2. DUPIXENT Immunology $531 25 payments
  3. COSENTYX $480 27 payments
  4. ILUMYA $369 17 payments
  5. SIMPONI ARIA $336 13 payments
  6. STELARA $336 13 payments
  7. SIMPONI $336 13 payments
  8. TALTZ $293 14 payments
  9. DUPIXENT Inflammation And Immunology $244 7 payments
  10. OLUMIANT $223 11 payments
  11. Other $3,225 153 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

246

Median for Nurse Practitioner: 389

Drug cost

$4,764

Median for Nurse Practitioner: $21,885

Branded share of claims

5.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tacrolimus Generic 14 $1,161
Clobetasol Propionate Generic 37 $765
Ketoconazole Generic 48 $747
Ipratropium-Albuterol Ipratropium/Albuterol Sulfate Brand 14 $683
Betamethasone Dipropionate Generic 12 $611
Triamcinolone Acetonide Generic 46 $362
Hydrocortisone Generic 50 $238
Minoxidil Generic 13 $101
Terbinafine Hcl Generic 12 $97

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $191
  • GENZYME CORPORATION $156
$347 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $206
$206 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $188
$188 — —
TREMFYA
  • Janssen Biotech, Inc. $129
$129 — —
SKYRIZI
  • AbbVie, Inc. $104
$104 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

241 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record